Haleon plc (HLNCF) Research

Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.

Market snapshot

Symbol
HLNCF
Price
$4.45
Day change
+4.81%
Market cap
$29.5B
P/E ratio
29.17x
52-week range
4.15-5.75
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 1 month

Peer companies

  • Chalice Brands Ltd. (CHALF)
  • Daiichi Sankyo Company, Limited (DSKYF)
  • Daiichi Sankyo Company, Limited (DSNKY)
  • HOYA Corporation (HOCPF)
  • Ipsen S.A. (IPSEY)
  • Merck KGaA (MKGAF)
  • Merck KGaA (MKKGY)
  • Takeda Pharmaceutical Company Limited (TKPHF)

Open Haleon plc (HLNCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.